No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing

Abstract

We investigated the expression of intercellular adhesion molecules ICAM-1 and ICAM-3 on peripheral blood mononuclear cells in a subgroup of 34 patients with relapsing-remitting multiple sclerosis who were treated orally with the chemokine receptor 1 antagonist BX 471 in a 16-week, randomised, double-blind, placebo-controlled phase II study. ICAM-1 and ICAM-3 expression was measured by flow cytometry at different time points during and after therapy and compared using multivariate analysis of variance and non-parametric Mann Whitney test. ICAM-3 expression on CD14⁺ peripheral blood mononuclear cells was increased in the verum group under therapy, but did not differ significantly between the verum and placebo groups. Most likely, this trend represents a small epiphenomenon only mediated by receptor cross-talk and feedback mechanisms.

Keywords

chemokine receptor 1 antagonist flow cytometry intercellular adhesion molecule-3 MRI multiple sclerosis receptor cross-talk

Get full access to this article

View all access options for this article.

References

Lebedeva T. , Dustin ML , Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 2005; 17: 251-258.

Montoya MC , Sancho D. , Bonello G. , et al. Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. Nat Immunol 2002; 3: 159-168.

Audran R. , Lesimple T. , Delamaire M. , Picot C. , Van Damme J. , Toujas L. Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages. Clin Exp Immunol 1996; 103: 155-160.

Kessel JM , Hayflick J. , Weyrich AS , et al. Coengagement of ICAM-3 and Fc receptors induces chemokine secretion and spreading by myeloid leukocytes. J Immunol 1998; 160: 5579-5587.

He M. , Horuk R. , Moochhala SM , Bhatia M. Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1173-G1180.

Trebst C. , Sørensen TL , Kivisäkk P. , et al. CCR1 +/ CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001; 159: 1701-1710.

Zipp F. , Hartung HP , Hillert J. , et al. Blockade of chemokine signaling in patients with multiple sclerosis . Neurology 2006; 67: 1880-1883.

Kraus J. , Oschmann P. , Engelhardt B. , et al. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 1998 ; 98: 102-109.

Fawcett J. , Holness CL , Needham LA , et al. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 1992 ; 360: 481-484.

10.

Montecucco F. , Burger F. , Pelli G. , et al. Statins inhibit Creactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology 2009; 48: 233-242.

11.

Babina M. , Mammeri K. , Henz BM Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion - evidence for retinoid signaling pathways in the mast cell lineage . J Leukoc Biol 2001; 69: 361-372.

No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing—remitting multiple sclerosis patients

Abstract

Keywords

Get full access to this article

References